Wilson Sonsini advised Think Bioscience on the deal.Think Bioscience, a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, announced it has raised…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
